Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Immunogenomic and ageing determinants of therapy response in brain metastasis

Project description

Personalising treatment for brain metastases

Brain metastases are a common and often fatal consequence of primary cancer. Although immunotherapies hold promise, a large fraction of patients remains unresponsive, likely due to the heterogeneity of their tumour immune microenvironment. Immune responses can be affected by genetics and ageing, but their interplay remains poorly understood. The ERC-funded IMMUNAGENOMICS project explores the impact of these factors on anti-tumoural immunity and therapy outcomes by combining novel methods such as single-cell sequencing, spatial transcriptomics and imaging. Project work could provide the basis for individually tailored, improved therapies for treating brain metastatic cancer.

Objective

Cancer represents a critical public health issue, with 2.74 million new cases diagnosed in Europe in 2022. Most cancer-related deaths are attributed to metastatic spread and it is estimated that 20-40% of all cancer patients will develop metastases to the brain (BrM), facing a dismal prognosis. Novel immunotherapies have shown promising outcomes in BrM patients, although a substantial proportion remain unresponsive. This reflects the heterogeneous nature of the tumor immune microenvironment (TIME) and emphasizes the need for a better understanding of its role driving pro- or anti-tumoral responses. My postdoctoral research suggested an important role for genetic variation in human BrM cancer cells regulating the composition and function of the TIME. Likewise, ageing has a major impact in the ability of the immune system to fight cancer. However, how these two key factors interact and influence responses to therapy remains unknown.

IMMUNAGENOMICS aims to transform personalized care for BrM patients by offering a multidisciplinary view on the dynamic regulation of the TIME by ageing and genetic variation. Specifically, we will: (i) characterize changes in baseline immunity along ageing;(ii) evaluate responses to radio- and immunotherapy in young and aged mouse models of BrM bearing different somatic mutations; (iii) analyze the TIME of BrM tumors from young and aged mice, pre and post-treatment by complementary orthogonal approaches including: flow cytometry, hyperplexed immunofluorescence imaging, scRNA-Seq and spatial transcriptomics; (iv) examine the link between ageing, genetic variation, TIME phenotypes and responses to therapy in collections of banked human BrM samples.

Overall, I envision that IMMUNAGENOMICS will help decipher the complex interplay between ageing and genomic variation shaping immune responses against BrM tumors, ultimately opening new perspectives for the development of more effective personalized therapies for this devastating form of cancer

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

LUXEMBOURG INSTITUTE OF HEALTH
Net EU contribution
€ 1 499 980,00
Address
1A RUE RUE THOMAS EDISON
1445 Strassen
Luxembourg
Region
Luxembourg Luxembourg Luxembourg
Activity type
Research Organisations
Links
Total cost
€ 1 499 980,00

Beneficiaries (1)